Rekah Pharmaceutical (Israel) Price Prediction
| REKA Stock | ILA 1,499 110.00 7.92% |
Oversold Vs Overbought
58
Oversold | Overbought |
Using Rekah Pharmaceutical hype-based prediction, you can estimate the value of Rekah Pharmaceutical Industry from the perspective of Rekah Pharmaceutical response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Rekah Pharmaceutical to buy its stock at a price that has no basis in reality. In that case, they are not buying Rekah because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Rekah Pharmaceutical after-hype prediction price | ILA 1499.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Rekah |
Rekah Pharmaceutical After-Hype Price Prediction Density Analysis
As far as predicting the price of Rekah Pharmaceutical at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Rekah Pharmaceutical or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Rekah Pharmaceutical, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Rekah Pharmaceutical Estimiated After-Hype Price Volatility
In the context of predicting Rekah Pharmaceutical's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Rekah Pharmaceutical's historical news coverage. Rekah Pharmaceutical's after-hype downside and upside margins for the prediction period are 1,495 and 1,503, respectively. We have considered Rekah Pharmaceutical's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Rekah Pharmaceutical is very steady at this time. Analysis and calculation of next after-hype price of Rekah Pharmaceutical is based on 3 months time horizon.
Rekah Pharmaceutical Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Rekah Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rekah Pharmaceutical backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Rekah Pharmaceutical, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.11 | 3.54 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1,499 | 1,499 | 0.00 |
|
Rekah Pharmaceutical Hype Timeline
Rekah Pharmaceutical is at this time traded for 1,499on Tel Aviv Stock Exchange of Israel. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Rekah is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at 0.11%. %. The volatility of related hype on Rekah Pharmaceutical is about 0.0%, with the expected price after the next announcement by competition of 1,499. About 37.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rekah Pharmaceutical last dividend was issued on the 6th of April 2022. Assuming the 90 days trading horizon the next forecasted press release will be within a week. Check out Rekah Pharmaceutical Basic Forecasting Models to cross-verify your projections.Rekah Pharmaceutical Related Hype Analysis
Having access to credible news sources related to Rekah Pharmaceutical's direct competition is more important than ever and may enhance your ability to predict Rekah Pharmaceutical's future price movements. Getting to know how Rekah Pharmaceutical's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Rekah Pharmaceutical may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BEZQ | Bezeq Israeli Telecommunication | 0.00 | 0 per month | 1.32 | 0.08 | 3.25 | (2.35) | 8.84 | |
| BRIN | Brainsway | 0.00 | 0 per month | 3.05 | 0.10 | 6.92 | (5.26) | 23.11 | |
| MVNE | Mivne Real Estate | 0.00 | 0 per month | 2.05 | 0.03 | 3.23 | (3.25) | 8.25 | |
| PHTM | Photomyne | 0.00 | 0 per month | 1.00 | 0.10 | 2.13 | (1.96) | 6.33 | |
| ILDR | Israel Land Development | 0.00 | 0 per month | 2.10 | 0.03 | 5.38 | (4.49) | 11.17 | |
| GLBX | Glassbox | 0.00 | 0 per month | 2.69 | (0) | 3.65 | (3.49) | 24.81 | |
| CMCT | Creative Media Community | 0.00 | 0 per month | 0.00 | (0.29) | 3.50 | (15.01) | 64.54 |
Rekah Pharmaceutical Additional Predictive Modules
Most predictive techniques to examine Rekah price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Rekah using various technical indicators. When you analyze Rekah charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Rekah Pharmaceutical Predictive Indicators
The successful prediction of Rekah Pharmaceutical stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Rekah Pharmaceutical Industry, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Rekah Pharmaceutical based on analysis of Rekah Pharmaceutical hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Rekah Pharmaceutical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Rekah Pharmaceutical's related companies.
Story Coverage note for Rekah Pharmaceutical
The number of cover stories for Rekah Pharmaceutical depends on current market conditions and Rekah Pharmaceutical's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Rekah Pharmaceutical is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Rekah Pharmaceutical's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Rekah Pharmaceutical Short Properties
Rekah Pharmaceutical's future price predictability will typically decrease when Rekah Pharmaceutical's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Rekah Pharmaceutical Industry often depends not only on the future outlook of the potential Rekah Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rekah Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 11.4 M |
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |